C-myb蛋白、4E-BP1蛋白在NK/T细胞淋巴瘤中的表达与预后的关系  

Expression of C-myb protein and 4E-BP1 protein in NK/T-cell lymphoma and its relationship with prognosis

作　　者：崔红丽 贾洪菊[1] 许杰[2] CUI Hong-li;JIA Hong-ju;XU Jie(Department of Tumor Radiotherapy,the First Hospital of Qinhuangdao,Qinhuangdao Hebei 066000,China;Department of Joint Surgery,the First Hospital of Qinhuangdao,Qinhuangdao Hebei 066000,China)

机构地区：[1]秦皇岛市第一医院肿瘤放射治疗科,河北秦皇岛066000 [2]秦皇岛市第一医院关节外科,河北秦皇岛066000

出　　处：《临床和实验医学杂志》2023年第20期2165-2168,共4页Journal of Clinical and Experimental Medicine

基　　金：河北省卫健委科技计划支撑项目(编号:20210495);秦皇岛市科学技术研究与发展计划项目(编号:202101A084)。

摘　　要：目的探讨转录激活因子Myb(C-myb)、真核细胞翻译起始因子4E结合蛋白-1(4E-BP1)蛋白在NK/T细胞淋巴瘤中的表达及与预后的关系。方法回顾性选取2017年12月至2019年12月在秦皇岛市第一医院治疗的NK/T细胞淋巴瘤患者34例作为观察组,同时选取腺样体肥大组织30例作为对照组。采用免疫组织化学法检测C-myb、4E-BP1表达,比较两组患者C-myb、4E-BP1表达情况,分析观察组C-myb、4E-BP1表达与临床病理关系。采用Spearman秩相关分析C-myb和4E-BP1表达相关性。随访患者总体生存时间,分析C-myb、4E-BP1表达与预后的关系。结果观察组C-myb和4E-BP1阳性表达率分别为55.88%和61.76%,明显高于对照组(10.00%、6.67%),差异均有统计学意义(P<0.05)。临床分期Ⅲ~Ⅳ患者C-myb阳性表达率为91.67%,明显高于Ⅰ~Ⅱ患者(36.36%),差异有统计学意义(P<0.05);不同性别、年龄、原发部位、B症状、国际预后指数(IPI)指数及淋巴结侵犯患者C-myb阳性表达率比较,差异均无统计学意义(P>0.05)。IPI指数≤2分患者4E-BP1阳性表达率为76.00%,明显高于IPI指数>2分患者(22.22%),差异有统计学意义(P<0.05);不同性别、年龄、原发部位、B症状、临床分期及淋巴结侵犯患者4E-BP1阳性表达率比较,差异均无统计学意义(P>0.05);C-myb和4E-BP1表达呈正相关(r_(s)=0.642,P<0.05);C-myb阳性表达和阴性表达患者中位总生存时间比较,差异无统计学意义(P>0.05);4E-BP1阳性表达患者中位总生存时间为24个月(95%CI:21.15~26.85),明显短于4E-BP1阴性表达患者的33个月(95%CI:32.20~33.80),差异有统计学意义(P<0.05)。结论NK/T细胞淋巴瘤中C-myb和4E-BP1蛋白表达上调,与临床分期、IPI指数有一定关系,其中4E-BP1表达与患者预后可能有一定联系。Objective To investigate the expression of transcription activator myb(C-myb)and eukaryotic translation initiation factor 4E binding protein-1(4E-BP1)protein in NK/T-cell lymphoma and their relationship with prognosis.Methods Thirty four patients with NK/T-cell lymphoma treated in the First Hospital of Qinhuangdao from December 2017 to December 2019(observation group)and 30 patients with adenoid hypertrophy tissue were selected as control group,the expression of C-myb protein and 4E-BP1 protein was detected by immunohistochemistry,and the overall survival time was followed up.Results The positive expression rates of C-myb and 4E-BP1 in the observation group were 55.88%and 61.76%,which were significantly higher than those in the control group(10.00%,6.67%),the differences were statistically significant(P<0.05).The positive expression rate of C-myb in patients with clinical stageⅢ-Ⅳwas 91.67%,which was significantly higher than that in patients withⅠ-Ⅱ(36.36%),the difference was statistically significant(P<0.05);there were no statistically significant differences in c-myb positive expression rate among patients with different genders,ages,primary sites,symptoms of B,international prognostic index(IPI)index and lymph node invasion(P>0.05).The positive expression rate of 4E-BP1 in patients with IPI≤2 was 76.00%,which was significantly higher than that in patients with IPI>2(22.22%),the difference was statistically significant(P<0.05);there was no statistically significant difference in the positive expression rate of 4E-BP1 in patients with different gender,age,primary site,B symptom,clinical stage and lymph node invasion(P>0.05),there was a positive correlation between C-myb and 4E-BP1(r_(s)=0.642,P<0.05).There was no statistically significant difference in median overall survival time between C-myb positive and negative expression patients(P>0.05);The median overall survival time of patients with positive expression of 4E-BP1 was 24 months(95%CI:21.15-26.85),which was significantly less than that of patie

关 键 词：转录激活因子Myb 真核细胞翻译起始因子4E结合蛋白-1 NK/T细胞淋巴瘤 预后 临床病理特征 

分 类 号：R733.1[医药卫生—肿瘤]